|
|
||||||||
1 Department of Chemistry, State University of New York at Stony Brook, Stony Brook, New York 11794-3400, USA
2 Graduate Program in Biophysics and Graduate Program in Molecular and Cellular Biology, State University of New York at Stony Brook, Stony Brook, New York 11794, USA
Reprint requests to: Daniel P. Raleigh, Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY 11794-3400; e-mail: draleigh{at}notes.cc.sunysb.edu; fax: (631) 632-7960.
(RECEIVED November 20, 2000; FINAL REVISION November 5, 2001; ACCEPTED November 5, 2001)
3 Present address: Oxford Centre for Molecular Sciences, New Chemistry Laboratory, South Parks Road, Oxford University, Oxford OX1 3QH, United Kingdom. ![]()
Article and publication are at http://www.proteinscience.org/cgi/doi/10.1110/ps.48702.
| Abstract |
|---|
|
|
|---|
Keywords: Amylin; islet amyloid polypeptide; IAPP; amyloid; deamidation; protein aggregation; diabetes mellitus; chemical modification
Abbreviations: ACN, acetonitrile Asn, asparagine Asp, aspartic acid CCA,
-cyano-4-hydroxycinnamic acid FTIR, Fourier transform infrared spectroscopy isoAsp, isoaspartic acid MALDI-MS, matrix-assisted laser desorption ionization mass spectrometry RP-HPLC, reversed-phase high-performance liquid chromatography TEM, transmission electron microscopy
| Introduction |
|---|
|
|
|---|
Amyloidogenic proteins and polypeptides are notoriously difficult to prepare, purify, and analyze. Consequently, many groups have used smaller peptide fragments derived from the protein of interest as convenient model systems (Halverson et al. 1991; Shen et al. 1993; Baumann et al. 1996; Inouye and Kirschner 1997; Guijarro et al. 1998; Sherzinger et al. 1999). Our own work has focused on the polypeptide hormone, amylin, which is responsible for the amyloid deposits in the pancreas of patients with Type 2 diabetes mellitus. A peptide corresponding to residues 20 to 29 of human amylin (amylin2029, sequence SNNFGAILSS) is widely used as a model system to study amyloid formation by amylin (Glenner et al. 1988; Betsholtz et al. 1990; Westermark et al. 1990; Ashburn et al. 1992; Ashburn and Lansbury 1993; Griffiths et al. 1995). In this article we report that very low levels of asparagine deamidation can lead to significant changes in the propensity of amylin derived peptides to aggregate.
During the course of a study involving the replacement of the glycine residue in SNNFGAILSS with other amino acids we detected small amounts of deamidated material in several samples. Particularly dramatic effects were observed for a peptide with the sequence SNNFPAILSS. Strikingly, the peptide did not aggregate in the absence of the impurities, but spontaneous deamidation of trace amounts of material lead to aggregation. The amount of deamidated material that was required to cause this change in behavior was very small (less than 5% of the total sample), and would typically not be detected by standard analytical methods. Deamidation lead to an unexpected pH dependence of the aggregation behavior, and furthermore, trace amounts of deamidated material can induce aggregation when added to freshly purified samples. Asparagine deamidation is one of the most common nonenzymatic modifications, and the results presented here indicate that it can, at least in some cases, have striking effects on the ability of peptides to aggregate.
| Results |
|---|
|
|
|---|
The impurities in these samples were identified as deamidation products using two methods, analytical HPLC, and a methyl esterification assay coupled with matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS). These experiments were performed on all the peptides in this study. The results reported here describe in detail the analysis of the SNNFPAILSS peptide.
HPLC has been used to characterize deamidation in other peptide systems, and the relative retention times for deamidated peptides and unmodified peptides have been reported (Aswad and Guzetta 1995). At pH 2, the Asn and iso-Asp derivatives normally elute first followed by the Asp derivatives. At pH 6, the Asp and iso-Asp derivatives will be deprotonated and typically elute first, followed by the Asn derivative (Fig. 1A
). The small impurities for SNNFPAILSS observed by HPLC eluted after the Asn containing peptide peak at pH 2 but before the Asn containing peptide peak at pH 5.5 (Fig. 1B
). This corresponds to the expected pH-dependent relative retention times for Asp/isoAsp derivatives. If the sample is subjected to conditions that promote deamidation (pH 8 and 60°C), the relative intensity of the peaks due to the impurities increases, providing additional indirect evidence that the minor peaks represent deamidation products (Fig. 1C
). The prominent deamidation peak observed in the HPLC trace of this sample run with the low pH mobile phase is smaller than the peak observed using the phosphate-based buffer system. This reflects the fact that the peak in the low pH buffers represents only the Asp peptide, but in the phosphate buffer system the peak represents Asp plus iso-Asp (see Fig. 1A
). When deamidation is promoted by this method, the ratio of iso-Asp to Asp is typically about 3:1, which is consistent with the observed relative peak heights. It is important to note that this experiment was conducted to confirm the relative retention times of deamidated and nondeamidated material. It should not be assumed that the same products or ratios of products would necessarily be formed as a result of spontaneous deamidation of a sample of the peptide in solution at lower temperature and neutral pH. Finally, a synthetic peptide with the sequence SNDFPAILSS coeluted with the impurities providing additional evidence that they arose from Asn deamidation.
|
1048 + 23 = 1071 g/mol). The formation of a complex with sodium is commonly observed in MALDI-MS. Methyl esterification of SNNFPAILSS resulted in the detection of two peaks corresponding to molecular weights of 1071 ± 2 g/mol and 1086 ± 2 g/mol. These peaks are due to SNNFPAILSS plus sodium and SNNFPAILSS plus sodium plus 14 from the methyl esterification (Fig. 2
|
|
|
It is important to note that independent aggregation of the deamidated impurity cannot account for the observed changes in the FTIR spectra or the TEM images. Only 5% of the material is deamidated, yet the ß-sheet peak in the FTIR spectrum corresponds to roughly 25% of the total spectral intensity, suggesting that on the order of 25% of the material has aggregated. The analysis assumes that the extinction coefficients for the ß-sheet and random coil bands are approximately equal. This is a common assumption in the interpretation of FTIR spectra. Qualitative examination of the TEM grids revealed that virtually the entire sample grid was covered with deposits, again arguing that more than just 5% of the material had aggregated. These observations are corroborated by the fact that the deamidated material can induce the nondeamidated sample to aggregate (Fig. 5
).
|
Deamidation is not restricted to the SNNFPAILSS peptide
We also examined several other peptides for the presence of deamidated material. Samples tested included variants in which the Gly residue of the wild-type sequence was replaced by L- or D-Ala and by D-Pro. All of the peptides with the exception of the D-Ala sample underwent spontaneous deamidation that lead to detectable amounts of material. The presence of trace amounts of deamidated material lead to clear changes in the aggregation of the D-Pro sample. We also observe effects, albeit more subtle, with the wild-type sequence. Deamidation of amylin2029 did result in modest changes in the FTIR spectra, but did not affect the ability of the peptide to form amyloid at high or low pH. It is likely that the intrinsic tendency of the SNNFGAILSS sequence to aggregate is so high that the presence or absence of deamidated material has little detectable effect on the observed aggregation behavior. The presence of low levels of impurities might, however, still affect the kinetics of aggregation of the wild-type sequence.
| Discussion |
|---|
|
|
|---|
In principle, the deamidation of a peptide could promote, inhibit, or have no effect on the aggregation behavior. In the case of the SNNFPAILSS peptide, it is clear that deamidation promotes aggregation, and it is interesting to speculate on the possible mechanism by which this peptide aggregates. Our pH-dependent studies indicate that the protonation state of the deamidation impurity plays a key role. This, in turn, suggests that any potential alterations in the backbone induced by the possible conversion of an Asn residue to an iso-Asp residue are likely to be of lesser importance than the ionization state of the newly introduced acidic side chain. At pD 2.25, the affected side chain of the deamidated impurities will be largely protonated and neutral. At pD 5.71, the affected side chain will be deprotonated and have a negative charge. This negative charge may initiate the aggregation via an electrostatic interaction with the positively charged N-terminus on another peptide molecule. Alternatively, a singly deamidated peptide would have no net charge at pD 5.71 but be positively charged at pD 2.25, which may explain the preferential aggregation at pD 5.71.
| Materials and methods |
|---|
|
|
|---|
Identification of deamidated peptides
Deamidation was characterized by analytical RP-HPLC and by a methyl esterification assay. The HPLC experiments were performed using a C18 analytical column (Vydac) and the phosphate and HCl buffers described in the peptide purification section. Methyl esterification of the peptides was used to detect the presence of deamidated material. The esterification was followed by MALDI-MS using a modification of the procedure outlined by Tuong et al. (1992). Methanolic HCl (2 M) was prepared by the addition of 5 mL acetyl chloride to 30 mL MeOH. The addition was performed under N2 at 0°C. The SNNFPAILSS peptide was placed in an eppendorf tube and 100 µL of methanolic HCl was added. The solution was briefly vortexed and the reaction performed at room temperature. Aliquots of the reaction solution were removed, quenched with a fourfold volume of water, and stored at 0°C until analyzed. Sample aliquots were analyzed by MALDI-MS using
-cyano-4-hydroxycinnamic acid (CCA) as the matrix. The CCA matrix solution was prepared by dissolving the CCA in a solution of methanolic HCl/H2O (1:4). Measured peak heights were used to estimate the relative amounts of deamidated and nondeamidated material. MALDI-MS was performed on a Bruker TOF instrument. Calibration was performed using at least three standards. All spectra were obtained in positive ion/reflectron mode.
Characterization of peptides by FTIR, TEM, and Congo Red birefringence
Most experiments were performed twice to ensure reproducibility. Peptide concentrations ranged from 3.5 to 5.1 mM. The pD value of the samples ranged from pD 1.13 to 2.29 and pD 5.47 to 5.80 and were corrected for isotope effects. Samples were dissolved in D2O, incubated at room temperature for 30 min, and lyophilized overnight to remove residual water. The samples were then redissolved in D2O, and the FTIR spectra were recorded and corrected for background. TEM was performed after 1 or 7 d of incubation at room temperature. Experimental details of the FTIR, TEM, and amino acid analysis procedures can be found elsewhere (Nilsson and Raleigh 1999). In brief, FTIR was performed on a Biorad FTS-40A spectrometer using a DTGS detector with 2 cm-1 resolution at 23°C. A dismountable sample cell (CaF2 plates) was used with a 0.05 mm Teflon spacer. The amide I band (16001700 cm-1) was fit using the Biorad software with a linear baseline correction. All parameters were allowed to vary and successive iterations resulted in a reasonable fit. The spectrum of the pD 5.71 sample of SNNFPAILSS that contains deamidation impurities, however, required the values for the full width at half height to be fixed to achieve a reasonable fit. TEM was performed at the University Microscopy Imaging Center at the State University of New York at Stony Brook. Samples were placed on a carbon-coated Formvar 200 mesh copper grid and negatively stained with uranyl acetate and imaged using a JOEL 1200EX TEM operating at 80 kEV. Amino acid analysis was performed at Commonwealth Biotechnologies, Inc. Congo Red staining was performed on a peptide sample that was air dried on a superfrost microscope slide. The peptide was stained using an 80% ethanol solution that was saturated with sodium chloride and Congo Red. Excess staining solution was removed and the slides were analyzed using either a Nikon SMZ-2T polarizing microscope (10 to 60x) or a Nikon Labophot-pol laboratory polarizing microscope (50 to 400x). The birefringence was very weak using the Nikon SMZ-2T microscope, possibly due to imperfections in the lens and the low magnification, but the Labophot-pol microscope revealed birefringence that was significantly more pronounced.
Seeding experiments
Deamidation impurities were isolated by HPLC. Phosphate buffers were used for separation because the peak resolution is much better under these conditions (Fig. 1
). The samples were desalted by HPLC using HCl buffers. Both samples were then dissolved in D2O, lyophilized to remove residual water, resuspended in D2O, and the pD adjusted to pD 5.65 using DCl/NaOD. The sample of pure SNNFPAILSS peptide was divided in half to generate two samples of equal concentration at the same pD. The deamidation impurities were suspended in a minimal volume of D2O and added to one sample of the SNNFPAILSS. Both samples were incubated at 25°C and monitored by FTIR. FTIR spectra were recorded on the day of sample preparation (designated day 0) and on days 1, 2, 3, 4, 8, and 20.
| Acknowledgments |
|---|
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
| References |
|---|
|
|
|---|
Ashburn, T.T., Auger, M., 1st., and Lansbury, P.T., Jr. 1992. The structural basis of pancreatic amyloid formation: Isotope-edited spectroscopy in the solid state. J. Am. Chem. Soc. BO114: 790791.[CrossRef]
Aswad, D.W. and Guzetta, A.W. 1995. Methods for analysis of deamidation and isoaspartate formation in peptides and proteins. In Deamidation and isoaspartate formation in peptides and proteins (ed. D.W. Aswad), pp. 829. CRC Press, Ann Arbor, MI.
Baumann, M.H., Wisniewski, T., Levy, E., Plant, G.T., and Ghiso, J. 1996. C-terminal fragments of alpha- and beta-tubulin form amyloid fibrils in vitro and associate with amyloid deposits of familial cerebral amyloid angiopathy, British type. Biochem. Biophys. Res. Commun. 219:238242.[CrossRef][Medline]
Betsholtz, C., Christmansson, L., Engstrom, U., Rorsman, F., Jordan, K., O'Brien, T.D., Murtaugh, M., Johnson, K.H., and Westermark, P. 1990. Structure of cat islet polypeptide and identification of amino acid residues of potential significance for islet amyloid formation. Diabetes 39: 118122.[Abstract]
Chirgadze, Y.N., Fedorov, O.V., and Trushina, N.P. 1975. Estimation of amino acid residue side-chain absorption in the infrared spectra of protein solutions in heavy water. Biopolymers 14:679694.[CrossRef][Medline]
Chirgadze, Y.N., Shestopalov, B.V., and Venyaminov, S.Y. 1973. Intensities and other spectral parameters of infrared amide bands of polypeptides in the ß- and random forms. Biopolymers 12:13371351.[CrossRef][Medline]
Cribbs, D.H., Azizeh, B.Y., Cotman, C.W., and LaFerla, F.M. 2000. Fibril formation and neurotoxicity by a herpes simplex virus glycoprotein B fragment with homology to the Alzheimer's Aß peptide. Biochemistry 39:59885994.[CrossRef][Medline]
Fabin, H., Szendrei, G.I., Mantsch, H.H., Greenberg, B.D., and Otovos, L., Jr. 1994. Synthetic post-translationally modified human Aß peptide exhibits a markedly increased tendency to form ß-pleated sheets in vitro. Eur. J. Biochem. 221:959964.[Medline]
Fandrich, M., Fletcher, M.A., and Dobson, C.M. 2001. Amyloid fibrils from muscle myoglobin. Nature 410:165166.[CrossRef][Medline]
Glenner, G.G., Eanes, E.D., and Wiley, C.A. 1988. Amyloid fibrils formed from a segment of the pancreatic-islet amyloid protein. Biochem. Biophys. Res. Commun. 155:608614.[CrossRef][Medline]
Griffiths, J.M., Ashburn, T.T., Auger, M., 1st, Costa, P.R., Griffin, R.G., and Lansbury, P.T., Jr. 1995. Rotational resonance solid-state NMR elucidates a structural model of pancreatic amyloid. J. Am. Chem. Soc. 117:35393546.[CrossRef]
Guijarro, J.I., Sunde, M., Jones, J.A., Campbell, I.D., and Dobson, C.M. 1998. Amyloid fibril formation by an SH3 domain. Proc. Natl. Acad. Sci. 95:42244228.
Halverson, K.J., Sucholeiki, I., Ashburn, T.T., and Lansbury, P.T., Jr. 1991. Location of ß -sheet-forming sequences in amyloid proteins by FTIR. J. Am. Chem. Soc. 113:67016703.[CrossRef]
Harper, J.D., Wong, S.S., Lieber, C.M., and Lansbury, P.T., Jr. 1997. Observation of metastable Aß amyloid protofibrils by atomic force microscopy. Chem. Biol. 4:119125.[CrossRef][Medline]
Higham, C.E., Jaikaran, E.T.A.S., Fraser, P.E., Gross, M., and Clark, A. 2000. Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Lett. 470:5560.[CrossRef][Medline]
Inouye, H. and Kirschner, D.A. 1997. X-ray diffraction analysis of scrapie prion: Intermediate and folded structures in a peptide containing two putative alpha-helices. J. Mol. Biol. 268:375389.[CrossRef][Medline]
Jackson, M. and Mantsch, H.H. 1995. The use and misuse of FTIR spectroscopy in the determination of protein structure. Crit. Rev. Biochem. Mol. Biol. 30:95120.[Medline]
Johnson, B.A. and Asward, D.W. 1995 Deamidation and isoaspartate formation during in vitro aging of purified proteins In Deamidation and isoaspartate formation in peptides and proteins (ed. D.W. Aswad), pp. 92113. CRC Press, Ann Arbor, MI.
Jost, K., Varga, J., Penke, B., and Zarandi, M. 2001. In vitro degradation of ß-amyloid [2535] peptide. Protein Pept. Lett. 8:423429.
Kowalewski, T. and Holtzman, D.M. 1999. In situ atomic force microscopy study of Alzheimer's ß-amyloid peptide on different substrates: new insights into mechanism of ß-sheet formation. Proc. Natl. Acad. Sci. 96:36883693.
Kuo, Y.-M., Emmerling, M.R., Woods, A.S., Cotter, R.J., and Roher, A.E. 1997. Isolation, chemical characterization, and quantitation of Aß 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem. Biophys. Res. Commun. 237:188191.[CrossRef][Medline]
Litvinovich, S.V., Brew, S.A., Aota, S., Akiyama, S.K., Haudenschild, C., and Ingham, K.C. 1998. Formation of amyloid-like fibrils by self-association of a partially folded fibronectin type III module. J. Mol. Biol. 280:245258.[CrossRef][Medline]
Middaugh, C.R., Mach, H., Ryan, J.A., Sanyal, G., and Volkin, D.B. 1995. Methods in molecular biology, vol. 40: Protein stability and folding: Theory and practice (ed. B.A. Shirley). Humana Press Inc., Totowa, NJ.
Miyata, T., Iida, Y., Ueda, Y., Shinzato, T., Seo, H., Monnier, V.M., Maeda, K., and Wada, Y. 1996. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products. Kidney Int. 49:538550.[Medline]
Moriarty, D.F. and Raleigh, D.P. 1999. Effects of sequential proline substitutions on amyloid formation by human amylin 2029. Biochemistry 38:18111818.[CrossRef][Medline]
Morozova-Roche, L.A., Zurdo, J., Spencer, A., Noppe, W., Receveur, V., Archer, D.B., Joniau, M., and Dobson, C.M. 2000. Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J. Struct. Biol. 130:339351.[CrossRef][Medline]
Nilsson, M.R. and Raleigh, D.P. 1999. Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. J. Mol. Biol. 294: 13751385.[CrossRef][Medline]
Robinson, A.B. and Rudd, C.J. 1974. Deamidation of glutaminyl and asparaginyl residues in peptides and proteins. In Current topics in cellular regulation (eds. B.L. Horecker and E.R. Stadtman), p. 8. Academic Press, New York.
Shen, C.-L., Scott, G.L., Merchant, F., and Murphy, R.M. 1993. Light scattering analysis of fibril growth from the amino-terminal fragment beta(128) of beta-amyloid peptide. Biophys. J. 65: 23832395.
Shimizu, T., Wantanabe, A., Ogawara, M., Mori, H., and Shirasawa, T. 2000 Isoasparate formation and neurodegeneration in Alzheimer's disease. Arch. Biochem. Biophys. 381: 225234.
Sherzinger, E., Sittler, A., Schweiger, K., Heiser, V., Lurz, R., Hasenbank, R., Bates, G.P., Lehrach, H., and Wanker, E.E. 1999. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. 96: 46044609.
Sipe, J.D. 1994. Amyloidosis. Crit. Rev. Clin. Lab. Sci. 31: 325354.[Medline]
Soto, C., Castaño, E.M., Kumar, R.A., Beavis, R.C., and Frangione, B. 1995. Fibrillogenesis of synthetic amyloid-ß peptides is dependent on their initial secondary structure. Neurosci. Lett. 200: 105108.[CrossRef][Medline]
Tenidis, K., Waldner, M., Bernhagen, J., Fischle, W., Bergmann, M., Weber, M., Merkle, M.-L., Voelter, W., Brunner, H., and Kapurniotu, A. 2000. Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J. Mol. Biol. 295: 10551071.[CrossRef][Medline]
Tuong, A., Maftouh, M., Ponthus, C., Whitechurch, O., Roitsch, C., and Picard, C. 1992. Characterization of the deamidated forms of recombinant hirudin. Biochemistry 31: 82918299.[CrossRef][Medline]
Tyler-Cross, R. and Schirch, V. 1991. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J. Biol. Chem. 266: 2254922556.
Westermark, P., Engström, U., Johnson, K.H., Westermark, G.T., and Betsholtz, C. 1990. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 87: 50365040.
Wright, H.T. 1991. Nonenzymatic deamidation of asparaginyl and glutaminyl residues in proteins. Crit. Rev. Biochem. Mol. Biol. 26: 152.[Medline]
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
T. Takata, J. T. Oxford, B. Demeler, and K. J. Lampi Deamidation destabilizes and triggers aggregation of a lens protein, {beta}A3-crystallin Protein Sci., September 1, 2008; 17(9): 1565 - 1575. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lavatelli, D. H. Perlman, B. Spencer, T. Prokaeva, M. E. McComb, R. Theberge, L. H. Connors, V. Bellotti, D. C. Seldin, G. Merlini, et al. Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue Mol. Cell. Proteomics, August 1, 2008; 7(8): 1570 - 1583. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Tcherkasskaya Photo-activity induced by amyloidogenesis Protein Sci., April 1, 2007; 16(4): 561 - 571. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Flaugh, I. A. Mills, and J. King Glutamine Deamidation Destabilizes Human {gamma}D-Crystallin and Lowers the Kinetic Barrier to Unfolding J. Biol. Chem., October 13, 2006; 281(41): 30782 - 30793. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R.H. Krebs, L. A. Morozova-Roche, K. Daniel, C. V. Robinson, and C. M. Dobson Observation of sequence specificity in the seeding of protein amyloid fibrils Protein Sci., July 1, 2004; 13(7): 1933 - 1938. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zhang, E. T. Powers, J. Nieva, M. E. Huff, M. A. Dendle, J. Bieschke, C. G. Glabe, A. Eschenmoser, P. Wentworth Jr., R. A. Lerner, et al. Metabolite-initiated protein misfolding may trigger Alzheimer's disease PNAS, April 6, 2004; 101(14): 4752 - 4757. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gotte, M. Libonati, and D. V. Laurents Glycosylation and Specific Deamidation of Ribonuclease B Affect the Formation of Three-dimensional Domain-swapped Oligomers J. Biol. Chem., November 21, 2003; 278(47): 46241 - 46251. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Nilsson and C. M. Dobson Chemical modification of insulin in amyloid fibrils Protein Sci., November 1, 2003; 12(11): 2637 - 2641. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |